Titlebook: Gastrointestinal Stromal Tumor; Research and Practic Yukinori Kurokawa,Yoshito Komatsu Book 2019 Springer Nature Singapore Pte Ltd. 2019 Ga

Iridescent

書目名稱Gastrointestinal Stromal Tumor影響因子(影響力)




書目名稱Gastrointestinal Stromal Tumor影響因子(影響力)學(xué)科排名




書目名稱Gastrointestinal Stromal Tumor網(wǎng)絡(luò)公開度




書目名稱Gastrointestinal Stromal Tumor網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Gastrointestinal Stromal Tumor被引頻次




書目名稱Gastrointestinal Stromal Tumor被引頻次學(xué)科排名




書目名稱Gastrointestinal Stromal Tumor年度引用




書目名稱Gastrointestinal Stromal Tumor年度引用學(xué)科排名




書目名稱Gastrointestinal Stromal Tumor讀者反饋




書目名稱Gastrointestinal Stromal Tumor讀者反饋學(xué)科排名

Antarctic

凌辱

Book 2019oplasms arising within the gastrointestinal tract. The causative gene of this disease was originally discovered in Japan by Prof. Seichi Hirota in 1998, and since then numerous important advances – from basic to clinical aspects – have been reported from Japan. Professionals involved in the manageme

窩轉(zhuǎn)脊椎動物

https://doi.org/10.1007/978-3-662-00599-6red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.

偶然

,Modellrechnung zur Chemie der Atmosph?re,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.

Grasping

Epidemiology,red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.

Grasping

Treatment Guidelines,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.

decode

痛打

First-Line Treatment,ct of imatinib is the trough level of imatinib. Although the treatment results improved, primary resistant cases, in which the effect of imatinib cannot be expected from the beginning, and secondary resistant cases, in which the effect was exhibited at the beginning but resistance was exhibited later, have become problematic.

無法治愈